{
  "docId": "019de077-7395-77e8-a759-85ee5ceb6441",
  "docSlug": "d10c7e5183f0665a04c27575aa737d7a",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2025-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 42,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide uses a three-row layout to highlight financial, clinical, and regulatory achievements.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-7395-77e8-a759-85ee5ceb6441/5",
  "deckHref": "/decks/019de077-7395-77e8-a759-85ee5ceb6441",
  "deckJsonHref": "/decks/019de077-7395-77e8-a759-85ee5ceb6441.json",
  "deckAnchorHref": "/decks/019de077-7395-77e8-a759-85ee5ceb6441#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.15,
        "x": 0.06,
        "y": 0.208
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "36e0eaaf-2f7a-4d99-90e5-d8dfd4197be7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.37,
        "x": 0.23,
        "y": 0.662
      },
      "kind": "list",
      "text": "8 NME approvals towards ambition of 20 by 2030",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a77877c-f01d-436a-a5dd-cd982f75d7c0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.37,
        "x": 0.23,
        "y": 0.208
      },
      "kind": "list",
      "text": "Delivered on upgraded FY 2024 financial guidance",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7694ec96-70ce-4b35-b2a4-f75856ab3a7a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.37,
        "x": 0.23,
        "y": 0.435
      },
      "kind": "list",
      "text": "9 positive high-value Phase III trial readouts in 2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac421553-1a26-4fe7-9dcd-d39cce2fbaac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.3,
        "x": 0.64,
        "y": 0.208
      },
      "kind": "metric",
      "text": "+21% Total Revenue (vs FY 2023)\n+19% Core EPS (vs FY 2023)\n+14% OpEx (vs FY 2023)",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee27f874-e837-49e0-a583-6051d625dd28",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.3,
        "x": 0.64,
        "y": 0.662
      },
      "kind": "paragraph",
      "text": "2 NME approvals since Q3 2024",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "57c6cc58-8b97-4526-940b-91ef07e1825e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.3,
        "x": 0.64,
        "y": 0.435
      },
      "kind": "paragraph",
      "text": "Multiple blockbuster opportunities with combined PYR >$5bn",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb2a1f54-ee19-4921-ad2c-76008ca79bf1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "All growth rates at CER. OpEx = Operating Expenses. 1. Full list of 2024 positive high-value Phase III readouts can be found in Appendix. 2. NME ambition tracking from date of first regulatory approval, dated from November 2022. Collaboration partner: Daiichi Sankyo (Datroway). Appendix: Glossary.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a49916c4-1f8e-40fd-b577-4f38da3b2a79",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Remarkable execution across key fundamentals in FY 2024",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d7eebaf-6ca2-4241-b914-86e450608b59",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 1,
      "beatId": "2cd4eb49-b01a-4c26-9070-0d551d07ea67",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Attention",
      "beatSlug": "monroes-sequence-attention",
      "evidence": "The opening slides grab attention with key takeaways and CEO opening remarks.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Hook",
      "parentBeatSlug": "hook"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 5,
      "name": "Aha Moment",
      "slug": "03-aha-moment",
      "bestFor": "Data-heavy sections, research findings, analytical arguments",
      "matchId": "9415618c-daeb-4b62-9cb4-fa78ec0188e5",
      "evidence": "The slides reveal the company's strong growth across focus therapy areas and emerging markets, providing an 'aha' moment for the audience.",
      "position": 0,
      "objective": "What are the key drivers of AstraZeneca's growth?",
      "structure": "The Problem/Question -> What the Data Shows -> The Insight",
      "confidence": 0.7,
      "description": "Establish a tension, present data, then deliver the insight that changes everything"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}